A COMPARATIVE STUDY ON THE EFFECTS OF BROMOCRIPTINE AND CABERGOLINE IN FEMALES WITH HYPERPROLACTINEMIC AMENORRHEA

Dr Eijaz Ahmed, Dr Ammara Khaliq, Dr Saqib Nasrullah
2020 Zenodo  
Dopamine agonists are the preferred treatment for most patients with hyperprolactinemia disorders. These agents are extremely effective in lowering serum prolactin levels, eliminating galactorrhea, restoring regular menstruation, and reducing tumor size. Dopamine agonists vary in efficacy and tolerability, including bromocriptine, quinagolide, and cabergoline. However, there are relatively few reports worldwide comparing the beneficial and undesirable effects of bromocriptine and cabergoline in
more » ... and cabergoline in the treatment of patients with hyperprolactinemia. Therefore, in this study an attempt was made to compare the efficacy and safety of cabergoline with bromocriptine in amenorrhoeic women with hyperprolactinemia. Place and Duration: In the Gynecology and Obstetric Unit II of Nishtar Hospital, Multan in collaboration with the Pharmacology department of Nishtar Medial University for six-months duration from January 2020 to June 2020. Patients and Methods: One hundred and thirty hyperprolactinemic amenorrhea women were randomized to either cabergoline (0.5 mg weekly) or bromocriptine (2.5 mg twice daily), randomly administered for 8 weeks. The clinical and biochemical status was assessed at the beginning and end of the study. Results: Amenorrhea was maintained in 9 women treated with cabergoline and 20 women treated with bromocriptine. Galactorrhea disappeared in the cabergoline group and persisted in 12 of the bromocriptine group. Normo-prolactinemia was achieved in 87.7% of women treated with cabergoline and 67.7% of women treated with bromocriptine. The reduction in prolactin levels is statistically greater in the cabergoline group compared to the bromocriptine group. Conclusion: Cabergoline and bromocriptine are effective in treating hyperprolactinemic amenorrhea. Cabergoline has advantages over bromocriptine in terms of both efficacy and toler [...]
doi:10.5281/zenodo.4161656 fatcat:lb56lwf4cbhdrp2456b7rkl7ra